Clinical Trials

Title   CL-PTL-126 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers
Description   This is a crossover study of Vigil, Atezolizumab and their combination in patients who have tumor harvested at surgery and successful manufacturing of Vigil but are ineligible for CL-PTL-119 (the VITAL study) or previously randomized to placebo.
IRB Number   17-071
Treatment   Oncology - Gynecology
Status   Active
Start Date   03/14/2017
Principal Name   Rodney Rocconi M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us